Bedard PL, Hyman DM, Davids MS, Siu LL (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078–1088. https://doi.org/10.1016/S0140-6736(20)30164-1

Article  CAS  PubMed  Google Scholar 

Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Cortés J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119. https://doi.org/10.1056/NEJMoa1113216

Article  CAS  PubMed  Google Scholar 

Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Eng J Med 373:1814–1823

Article  CAS  Google Scholar 

Chappell WH, Steelman LS, Long JM et al (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135–164

Article  PubMed  PubMed Central  Google Scholar 

Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mordant P, Loriot Y, Leteur C et al (2010) Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (everolimus) in combination. Mol Cancer Ther 9:358–368. https://doi.org/10.1158/1535-7163.MCT-09-1014

Article  CAS  PubMed  Google Scholar 

Piguet A-C, Saar B, Hlushchuk R et al (2011) Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10:1007–1017

Article  CAS  PubMed  Google Scholar 

Pignochino Y, Dell’Aglio C, Basiricò M et al (2013) The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 19:2117–2131

Article  CAS  PubMed  Google Scholar 

Yang J, Samsel PA, Narov K et al (2017) Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/− mice is superior to everolimus alone. Neoplasia 19:112–120

Article  PubMed  PubMed Central  Google Scholar 

Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

Article  CAS  PubMed  Google Scholar 

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

Article  CAS  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

Article  CAS  PubMed  Google Scholar 

Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. JCO 27:3312–3318

Article  CAS  Google Scholar 

Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brose MS, Troxel AB, Yarchoan M et al (2015) A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. JCO 33:6072–6072

Article  Google Scholar 

Cen P, Daleiden A, Doshi G, Amato R (2009) A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC). JCO 27:e16056–e16056. https://doi.org/10.1200/jco.2009.27.15_suppl.e16056

Article  Google Scholar 

Amato RJ, Flaherty AL, Stepankiw M (2012) Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin Genitourin Cancer 10:26–31

Article  PubMed  Google Scholar 

Chan JA, Mayer RJ, Jackson N et al (2013) Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol 71:1241–1246

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Simone P, Crocetti L, Pezzati D et al (2014) Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 46:241–244

Article  PubMed  Google Scholar 

Finn RS, Poon RTP, Yau T et al (2011) Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). JCO 29:4074–4074

Article  Google Scholar 

Finn RS, Poon RTP, Yau T et al (2013) Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 59:1271–1277

Article  CAS  PubMed  Google Scholar 

Giessinger S, Amato RJ, Jac J et al (2008) A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC). JCO 26:14603–14603

Article  Google Scholar 

Grignani G, Palmerini E, Ferraresi V et al (2015) Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 16:98–107

Article  CAS  PubMed  Google Scholar 

Hainsworth JD, Waterhouse DM, Penley WC et al (2013) Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI oncology research consortium. Cancer Investig 31:323–329

Article  CAS  Google Scholar 

Harzstark AL, Small EJ, Weinberg VK et al (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117:4194–4200

Article  CAS  PubMed  Google Scholar 

Koeberle D, Dufour J-F, Demeter G et al (2016) Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)†. Ann Oncol 27:856–861

Article  CAS  PubMed  Google Scholar 

Mattonet C, Nogova L, Scheffler M et al (2015) SORAVE: A phase I trial to evaluate safety and efficacy of combination therapy with everolimus and sorafenib. JCO 33:2550–2550

Article  Google Scholar 

Nogova L, Mattonet C, Scheffler M et al (2020) Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: a phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Med 9:4991–5007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raizer JJ, Grimm SA, Penas-Prado M et al (2015) A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: brain tumor treatment collaborative trial 09–01. JCO 33:2061–2061

Article  Google Scholar 

Sherman EJ, Ho AL, Fury MG et al (2015) Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. JCO 33:6069–6069

Article  Google Scholar 

Toffalorio F, Spitaleri G, Catania C et al (2014) Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. Oncol 19:344–345

Article  Google Scholar 

Kummar S, Chen HX, Wright J et al (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 9:843–856

Article  CAS  PubMed  Google Scholar 

El-Madani M, Hénin E, Lefort T et al (2015) Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations–example of EVESOR trial. Future Oncol 11:1511–1518

Article  CAS  PubMed  Google Scholar 

Kalra S, Rini BI, Jonasch E (2015) Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol 26:1300–1304

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark JW, Eder JP, Ryan D et al (2005) Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472–5480

Article  CAS  PubMed